Immunexpress Receives CE Mark and Signs European Commercialization Partnership for SeptiCyte® RAPID
- Thursday, March 26, 2020, 7:01
- Finance
- Add a comment
SEATTLE and BRISBANE, Australia, March 26, 2020 /PRNewswire/ — Immunexpress, Inc. a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced it has received CE Marking of SeptiCyte® RAPID for its host response technology. SeptiCyte® RAPID…
About the Author
adminasapcorp has written 41806 stories on this site.